Development and Regulation of Biologic Drugs – Comparison between Biologics and Biosimilars

Biologic medications, which are produced from live organisms, have significantly transformed the treatment of several diseases by providing precise therapies that are highly effective. Biosimilars have emerged as biologically similar alternatives to biologics, which are hard and expensive to create. However, it is important to note that biosimilars are not identical to the original medications. This abstract examines the fundamental distinctions between biologics and biosimilars, with a specific emphasis on their development procedures, regulatory prerequisites, and the difficulties encountered in guaranteeing their safety, effectiveness, and interchangeability. The study also emphasises the influence having biosimilars on healthcare expenses and availability, emphasising the significance of rigorous regulatory regimes in upholding therapeutic benchmarks.